Nipah virus vaccine trials are beginning

In Belgium, the first clinical trials of a vaccine developed against the Nipah virus are about to begin. This was reported by Zamin.uz.

This vaccine was developed by scientists from the University of Tokyo, and the trials are now planned to be conducted with human participants. According to Nikkei, this phase will assess the safety and efficacy of the vaccine.

Initial experiments were conducted on primates and showed a 100 percent success rate. Now, the main focus will be on studying the vaccine's effects on the human body.

Scientists plan to expand the trials in the future. In particular, additional studies may be conducted in Bangladesh involving adults and children.

It should be noted that recently reports emerged about the spread of the Nipah virus near Kolkata, India. This virus can be transmitted from animals, through contaminated food, or from person to person.

According to the World Health Organization, the fatality rate of Nipah virus infection can reach from 40 percent up to 75 percent. This rate depends on the quality of the local healthcare system and epidemic control measures.

Overall, the start of clinical trials for the vaccine is an important step. If the trials are successful, an effective means against the Nipah virus could be created, representing a significant achievement in the fight against this dangerous disease.